BiotechTube

ASP1650

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Incurable Platinum Refractory Germ Cell Tumors

Conditions

Incurable Platinum Refractory Germ Cell Tumors, Tumors

Trial Timeline

Mar 19, 2019 → Oct 16, 2020

NCT ID
NCT03760081

About ASP1650

ASP1650 is a phase 2 stage product being developed by Astellas Pharma for Incurable Platinum Refractory Germ Cell Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT03760081. Target conditions include Incurable Platinum Refractory Germ Cell Tumors, Tumors.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03760081Phase 2Completed

Competing Products

2 competing products in Incurable Platinum Refractory Germ Cell Tumors

See all competitors
ProductCompanyStageHype Score
omaveloxoloneAbbViePhase 1
33
Vandetanib + Gemcitabine + OxaliplatinAstraZenecaPhase 1
33

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85